Fournier Pharma and Xytis Pharmaceutcials sign licensing agreement for Anatibant
Fournier Pharma has granted Xytis an exclusive worldwide license for the development, manufacture and sale of the product containing its bradykinin B2 antagonist Anatibant for traumatic brain injury and possibly other indications. Fournier Pharma has retained full rights to manufacture the compound. The parties do not wish to disclose further details on the transaction.
Jean-Louis Junien, Chief Scientific Officer, Fournier Pharma, said: "Development in brain trauma is complex, but Anatibant is a very promising compound. Because its mechanism targets the treatment of cerebral edema, it should reduce early mortality, prevent long-term functional handicap and improve neurological outcome. I am pleased that this innovative compound from our Research Group is progressing into phase II with Xytis."
Dr. Werner Tschollar, founder and CEO of Xytis Pharmaceuticals Ltd., said: "Traumatic brain injury is an area of high unmet medical need. Anatibant belongs to the therapeutic class of bradykinin B2 inhibitors, which has demonstrated in previous clinical and non-clinical studies a potential benefit for the prevention of secondary brain damage in traumatic brain injury. We believe that Anatibant has a very good chance of becoming the first ever marketed drug improving TBI patients' clinical outcome."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.